Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Endoxifen is a non-steroidal triphenylethylene selective estrogen receptor modulator (SERM) and the active secondary metabolite of tamoxifen. It is not FDA-approved and remains investigational, studied in multiple Phase 1 and Phase 2 human trials for endocrine-refractory ER-positive breast cancer, desmoid tumors, and other hormone-receptor-positive solid tumors. Endoxifen is sold by research-chemical suppliers labeled for laboratory use only, not for human consumption.
0 of 1 vendors lab-verified
Verified purity per dollar — the cheapest that's actually been tested
No prices found for Endoxifen.
Single-vial list prices by default for a fair head-to-head — switch to Multi-vial / bulk for pack pricing. Estimates only; verify at vendor before purchase. For research use only. Not medical advice.
Kimera Chems has the lowest single-vial Endoxifen price at $0.062/mg among 3 COA-verified vendors on Disclosed Labs. Bulk or multi-vial deals may be lower.
What is the price range for Endoxifen?
Research-grade Endoxifen is listed at $0.062/mg from 1 verified source on Disclosed Labs.
How are Endoxifen prices verified on Disclosed Labs?
Every listed vendor holds a Grade C or better trust score, computed independently from lab Certificates of Analysis — not from payments or sponsorships. Prices are scraped and fact-checked daily. Vendors cannot pay to improve their ranking.
Check formulation: Lyophilized powder requires reconstitution before use. Pre-mixed solutions are more convenient but may have a shorter shelf life and higher prices.
Compare per-mg cost: Different strengths and quantities make direct price comparison difficult. Calculate the per-milligram cost to find the true best value.
Verify COAs: Look for vendors that publish per-batch Certificates of Analysis from named, accredited labs. Use the Full safety panel filter to require endotoxin, sterility, and heavy-metals testing on the current batch — not just HPLC purity.
No FDA approval or approval in any jurisdiction; endoxifen is investigational only. Human trials: Goetz et al. 2017 Phase 1 in endocrine-refractory metastatic ER-positive breast cancer (20–160 mg/day oral, no maximum tolerated dose, 3 partial responses, clinical benefit rate 26.3%); Takebe et al. 2021 Phase 1 in gynecologic, desmoid, and hormone-receptor-positive solid tumors (20–360 mg/day, no MTD, partial responses in desmoid tumors); Alliance A011203 randomized Phase 2 found Z-endoxifen not superior to tamoxifen overall but showed PFS benefit in CDK4/6-inhibitor-naive patients (HR 0.42). Preclinical: in ovariectomized mice, oral Z-endoxifen increased cancellous and cortical bone mass; in rats, reduced bone turnover and protected against bone loss; in MCF7 xenografts, showed superior antitumor activity versus tamoxifen, letrozole, and exemestane.
This platform provides informational tools only, not medical advice.
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer
2017
Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors
2021
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in ER-Positive, HER2-Negative Breast Cancer (Alliance A011203)
Prices verified as of July 2026. Actual prices may vary. For research use only.
2019
Disclosed Labs